Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

NCT02182297 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-07-18

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

The objective of this trial was to investigate safety, tolerability, and pharmacokinetics of BI 201335 ZW after administration of single rising doses from 40 mg to 480 mg of BI 201335 NA in healthy Japanese male volunteers.

Conditions

Healthy

Interventions

DRUG: BI 201335 NA in single rising doses
DRUG: Placebo

Sponsors & Collaborators

Boehringer Ingelheim
lead INDUSTRY

Study Design

Allocation: RANDOMIZED
Purpose: TREATMENT
Masking: DOUBLE
Model: PARALLEL

Eligibility

Min Age: 20 Years
Max Age: 35 Years
Sex: MALE
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2008-04-30
Primary Completion: 2008-12-31

More Related Trials

Entities

Drugs

Placebo

Companies

Boehringer Ingelheim

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Related Clinical Trials

Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

More Related Trials

Entities